Professor Sally Barrington Academics Professor of PET Imaging and NIHR Research Professor Contact details sally.barrington@kcl.ac.uk +44 (0) 20 7188 8364
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial Camilleri, M., Sive, J., Wilson, W., Pang, G., Jenner, R., Phillips, E., Popat, R., Ramasamy, K., Bygrave, C., Dadaga, T., Streetly, M., Cavenagh, J., Chapman, M., Barrington, S., Pike, L., Owen, R., Clifton-Hadley, L. & Yong, K., Jan 2021, In : British Journal of Haematology. 192, 1, p. e14-e16 Research output: Contribution to journal - Letter. DOIs: https://doi.org/10.1111/bjh.17168 Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma PETRA Consortium, Burggraaff, C. N., Rahman, F., Kaßner, I., Pieplenbosch, S., Barrington, S. F., Jauw, Y. W. S., Zwezerijnen, G. J. C., Müller, S., Hoekstra, O. S., Zijlstra, J. M., De Vet, H. C. W. & Boellaard, R., 1 Aug 2020, In : Molecular Imaging and Biology. 22, 4, p. 1102-1110 9 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1007/s11307-020-01474-z Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful ? Barrington, S. F., Zwezerijnen, B. G., de Vet, H. C., Heymans, M. W., Mikhaeel, N. G., Burggraaff, C. N., Eertink, J. J., Pike, L. C., Hoekstra, O. S., Zijlstra, J. M. & Boellaard, R., 17 Jul 2020, In : Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.2967/jnumed.119.238923 Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma Araf, S., Korfi', K., Bewicke-Copley, F., Wang, J., Cogliatti, S., Kumar, E., Forrer, F., Barrington, S. F., Graham, T. A., Scott, D. W., Rimsza, L. M., Davies, A., Johnson, P., Okosun, J., Fitzgibbon, J. & Fehr, M., 1 Jun 2020, In : Haematologica. 105, 6, p. E318-E321 Research output: Contribution to journal - Letter. DOIs: https://doi.org/10.3324/haematol.2019.242206 FDG-PET/CT after 2 cycles of RCHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - Final result of UK-NCRI prospective study Barrington, S., 20 May 2020, (Accepted/In press) In : British Journal of Haematology. Research output: Contribution to journal - Article Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study Mir, F., Barrington, S., Brown, H., Nielsen, T., Sahin, D., Meignan, M. & Trotman, J., 9 Apr 2020, In : Blood. 135, 15, p. 1214-1218 5 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1182/blood.2019001091 Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma Illidge, T. M., Phillips, E. H., Counsell, N., Pettengell, R., Johnson, P. W. M., Culligan, D. J., Popova, B., Clifton-Hadley, L., McMillan, A., Hoskin, P., Barrington, S. F. & Radford, J., 14 Jan 2020, In : Blood Advances. 4, 1, p. 203-206 4 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1182/bloodadvances.2019001023 FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study Mikhaeel, N. G., Cunningham, D., Counsell, N., McMillan, A., Radford, J. A., Ardeshna, K. M., Lawrie, A., Smith, P., Clifton-Hadley, L., O'Doherty, M. J. & Barrington, S. F., 1 Jan 2020, (Accepted/In press) In : British Journal of Haematology. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1111/bjh.16875 Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial Georgi, T. W., Kurch, L., Hasenclever, D., Warbey, V. S., Pike, L., Radford, J., Sabri, O., Kluge, R. & Barrington, S. F., 1 Jan 2020, In : PLoS ONE. 15, 4, e0231027. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1371/journal.pone.0231027 Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) Gibb, A., Pirrie, S. J., Linton, K., Warbey, V., Paterson, K., Davies, A. J., Collins, G. P., Menne, T., McKay, P., Fields, P. A., Miall, F. M., Nagy, E., Wheatley, K., Reed, R., Baricevic-Jones, I., Barrington, S. & Radford, J., 1 Jan 2020, (Accepted/In press) In : British Journal of Haematology. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1111/bjh.17073 View all publications
Course teacher: Nuclear Medicine: Science & Practice MSc/PG Dip/PG Cert Course teacher: Imaging Sciences Intercalated BSc